Article

Early Phase 2 data with high-dose aflibercept promising in wet AMD

Regeneron Pharmaceuticals announced at an ongoing Phase 2 trial has met its primary safety endpoint with no new safety signals observed.

Early Phase 2 data with high-dose aflibercept promising in wet AMD

Regeneron Pharmaceuticals Inc. announced that the ongoing Phase 2 proof-of-concept trial (NCT04126317) in which an 8-mg dose of aflibercept (Eylea) is being compared with a 2-mg dose for wet age-related macular degeneration (AMD), met the primary safety endpoint.

No new safety signals were observed compared to the approved 2-mg dose of the drug in 106 treatment-naïve patients with wet AMD (mean age, 77 years) randomly assigned to 1 of the 2 doses.

At the week-16 primary efficacy endpoint, the 8-mg dose resulted in 43.4% of patients having no retinal fluid compared with 26.4% treated with the 2-mg dose, a difference that trended toward significance (p = 0.067).

By 16 weeks, patients in both groups had received three initial doses at weeks 0, 4 and 8, after which dosing was extended to every 12 weeks or more frequently due to persistent/worsening disease.

Adverse events occurred in 17.0% of patients receiving the 8-mg dose and 22.6% receiving the 2-mg dose.

One serious ocular adverse event occurred in each group, i.e., a retinal tear in the 8-mg group and decreased vision in the 2-mg group.

No intraocular inflammation or arterial thromboembolic events or deaths occurred in either group.

The company expressed cautious optimism that the 8-mg dose of aflibercept will benefit patients with wet AMD.

Aflibercept is also being evaluated in 2 Phase 3 clinical trials for treating diabetic macular edema (PHOTON trial) and wet AMD (PULSAR trial). Both trials will assess the 8-mg dose of aflibercept compared to the 2-mg dose and test dosing intervals of every 12 weeks and every 16 weeks.

The Phase 3 studies are expected to announce results in the second half of 2022.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
© 2025 MJH Life Sciences

All rights reserved.